GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Conmed Corp (NYSE:CNMD) » Definitions » Beneish M-Score
中文

Conmed (Conmed) Beneish M-Score : -2.37 (As of Apr. 24, 2024)


View and export this data going back to 1987. Start your Free Trial

What is Conmed Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.37 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Conmed's Beneish M-Score or its related term are showing as below:

CNMD' s Beneish M-Score Range Over the Past 10 Years
Min: -2.75   Med: -2.52   Max: -2.37
Current: -2.37

During the past 13 years, the highest Beneish M-Score of Conmed was -2.37. The lowest was -2.75. And the median was -2.52.


Conmed Beneish M-Score Historical Data

The historical data trend for Conmed's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conmed Beneish M-Score Chart

Conmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.65 -2.67 -2.57 -2.47 -2.37

Conmed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 -2.37 -2.23 -2.35 -2.37

Competitive Comparison of Conmed's Beneish M-Score

For the Medical Devices subindustry, Conmed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conmed's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Conmed's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Conmed's Beneish M-Score falls into.



Conmed Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Conmed for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0635+0.528 * 1.0057+0.404 * 0.9758+0.892 * 1.1906+0.115 * 1.0062
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9306+4.679 * -0.026473-0.327 * 1.0007
=-2.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $242 Mil.
Revenue was 327.045 + 304.578 + 317.652 + 295.468 = $1,245 Mil.
Gross Profit was 182.175 + 168.059 + 170.69 + 155.321 = $676 Mil.
Total Current Assets was $616 Mil.
Total Assets was $2,300 Mil.
Property, Plant and Equipment(Net PPE) was $121 Mil.
Depreciation, Depletion and Amortization(DDA) was $72 Mil.
Selling, General, & Admin. Expense(SGA) was $503 Mil.
Total Current Liabilities was $311 Mil.
Long-Term Debt & Capital Lease Obligation was $973 Mil.
Net Income was 33.071 + 15.837 + 13.732 + 1.819 = $64 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 56.395 + 46.127 + 26.673 + -3.847 = $125 Mil.
Total Receivables was $191 Mil.
Revenue was 250.867 + 275.088 + 277.19 + 242.327 = $1,045 Mil.
Gross Profit was 131.862 + 151.615 + 151.777 + 135.991 = $571 Mil.
Total Current Assets was $581 Mil.
Total Assets was $2,298 Mil.
Property, Plant and Equipment(Net PPE) was $116 Mil.
Depreciation, Depletion and Amortization(DDA) was $70 Mil.
Selling, General, & Admin. Expense(SGA) was $454 Mil.
Total Current Liabilities was $297 Mil.
Long-Term Debt & Capital Lease Obligation was $985 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(242.279 / 1244.743) / (191.345 / 1045.472)
=0.194642 / 0.183023
=1.0635

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(571.245 / 1045.472) / (676.245 / 1244.743)
=0.546399 / 0.543281
=1.0057

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (615.649 + 120.722) / 2300.021) / (1 - (581.226 + 115.611) / 2297.592)
=0.679842 / 0.69671
=0.9758

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1244.743 / 1045.472
=1.1906

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(69.519 / (69.519 + 115.611)) / (71.874 / (71.874 + 120.722))
=0.375515 / 0.373185
=1.0062

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(503.038 / 1244.743) / (454.038 / 1045.472)
=0.40413 / 0.43429
=0.9306

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((973.14 + 310.729) / 2300.021) / ((985.076 + 296.552) / 2297.592)
=0.558199 / 0.557814
=1.0007

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(64.459 - 0 - 125.348) / 2300.021
=-0.026473

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Conmed has a M-score of -2.37 suggests that the company is unlikely to be a manipulator.


Conmed (Conmed) Business Description

Traded in Other Exchanges
Address
11311 Concept Boulevard, Largo, FL, USA, 33773
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgery. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
Executives
Peters Stanley W Iii officer: VP GM General Surgery C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Todd W. Garner officer: Executive Vice President & CFO C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Edward A. Clifford officer: VP Global Manufacturing C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Curt R Hartman director C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John D. Ferrell officer: Executive Vice President - HR C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Brian Concannon director HAEMONETICS CORP, 400 WOOD RD, BRAINTREE MA 02184-9144
Peter K Shagory officer: EVP,STRAT & CORP DEVT C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Daniel Jonas officer: Vice President/Legal Affairs, other: General Counsel C/O CONMED CORP, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Terence M Berge officer: VP Corp. Treasurer C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Johonna Marie Pelletier officer: Treasurer and VP, Tax C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Jerome J. Lande director 1 WORLD TRADE CENTER, 85TH FLOOR, NEW YORK NY 10007
Brent Lalomia officer: Vice President QA and RA C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
John Jed Kennedy officer: VP GM GI C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773
Mark E Tryniski director C/O CONMED CORP., 11311 CONCEPT BOULEVARD, LARGO FL 33773
Pat Beyer officer: President-Conmed International C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO FL 33773

Conmed (Conmed) Headlines